Drugs / HS-10382
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06530810 | Jul 2024 → May 2026 overdue | leukemia, myeloid, accelerated-phase | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05367700 | Apr 2022 → Dec 2024 overdue | leukemia, myeloid, accelerated-phase | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) hspharm.com ↗
At week 48, MMR achieved 80% and MR4.0 was 30%. |
| 2026-06-12 | Hansoh BioMedical R&D Company | Results EHA2026 | 翰森制药公布HS-10382（新型BCR::ABL1变构抑制剂）治疗慢性髓细胞性白血病（CML）两项研究数据 hansoh.cn ↗
研究结果显示，在第48周时，MMR率为80%，MR4. 0达30%. |
| 2023-06-05 | Hansoh BioMedical R&D Company | Results 2023 ASCO | 翰森制药B7-H3 ADC、c-MET TKI等研究成果亮相，临床潜力获国际权威认可 hansoh.cn ↗
在13例经中心实验室确认的EGFR敏感突变且MET扩增，缓解率61. 5%，5例确认的PR，4例SD. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) hspharm.com ↗ |
| 2026-06-12 | Hansoh BioMedical R&D Company | EHA2026 | 翰森制药公布HS-10382（新型BCR::ABL1变构抑制剂）治疗慢性髓细胞性白血病（CML）两项研究数据 hansoh.cn ↗ |
| 2023-06-05 | Hansoh BioMedical R&D Company | 2023 ASCO | 翰森制药B7-H3 ADC、c-MET TKI等研究成果亮相，临床潜力获国际权威认可 hansoh.cn ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10382 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05367700 ↗ |
| Action | Inhibit | “HS-10382 locks BCR-ABL1 into an inactive conformation.” NCT05367700 ↗ |
| Modality | Small molecule | “HS-10382 is a small molecular, oral potent, allosteric inhibitor.” NCT05367700 ↗ |
| Route | Oral | “HS-10382 is administered orally once daily.” NCT05367700 ↗ |